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Abstract 
Background and Purpose 
With the emergence of extensively drug-resistant tuberculosis there is a need for new 
anti-tubercular drugs that work through novel mechanisms of action. The meta cleavage 
product hydrolase, HsaD, has been demonstrated to be critical to the survival of 
Mycobacterium tuberculosis in macrophages and is encoded in an operon involved in 
cholesterol catabolism, which is identical in M. tuberculosis and M. bovis BCG.  
Experimental Approach 
We generated a mutant strain of M. bovis BCG with a deletion of hsaD and tested its 
growth on cholesterol. Using a fragment based approach, over 1,000 compounds were 
screened by a combination of differential scanning fluorimetry, NMR spectroscopy and 
enzymatic assay with pure recombinant HsaD to identify potential inhibitors. We used 
enzymological and structural studies to investigate derivatives of inhibitors identified and 
to test their effects on growth of M. bovis BCG and M. tuberculosis. 
Key Results  
The hsaD deleted strain is unable to grow on cholesterol as sole carbon source but can 
grow on glucose. Of seven chemically distinct “hits’’ from the library, two chemical 
classes of fragments were found to bind in the vicinity of the active siteof HsaD by X-ray 
crystallography. The compounds also inhibited  growth of M. tuberculosis on cholesterol. 
The most potent inhibitor of HsaD was found also to be the best inhibitor of 
mycobacterial growth on cholesterol-supplemented minimal medium. 
Conclusions and implications 
 We propose that HsaD is a novel therapeutic target which should be fully exploited in 
order to design and discover new anti-tubercular drugs 
 
Ligand  
Cholesterol Glycerol 
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Abbreviations: 4,9-DHSA, 4,5-9,10-diseco-3-hydroxy-5,9,17-trioxoandrosta-1(10), 2-diene-
4-oic acid; ADC, albumin-dextrose-catalase; BCG, Bacillus Calmette–Guérin; CHES, N-
Cyclohexyl-2-aminoethanesulfonic acid; DSF, differential scanning fluorimetry; FBDD, 
fragment based drug discovery; FCS, fetal calf serum; HOPDA, 2-hydroxy-6-oxo-6-
phenylhexa-2,4-dienoic acid; LB, Luria-Bertani; MB, Middlebrook; MCP, meta-cleavage 
product; MDR-TB, multidrug-resistant tuberculosis; MIC, minimum inhibitory 
concentration; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; NAT, 
arylamine N-acetyltransferase; OADC, oleic acid-albumin-dextrose-catalase; PMSF, 
phenylmethylsulfonyl fluoride; SAR, structure activity relationship; SPOTi, spot culture 
growth inhibition assay; STD, saturation transfer difference; TB, tuberculosis; TSP, 
(Trimethylsilyl)-propionic acid; WHO, World Health Organization; XDR-TB, extensively 
drug-resistant TB. 
 
Introduction   
Tuberculosis (TB) remains a global health emergency with an estimated 9 million new cases 
and 1.5 million deaths every year (WHO, 2015). Importantly, 3.7% of new cases and 20% of 
previously treated patients are infected with multidrug-resistant tuberculosis (MDR-TB). 
Moreover, up to 9% of these MDR-TB cases are resistant to nearly all known treatments and 
considered as extensively drug resistant TB (XDR-TB). Current treatment modalities for 
drug-sensitive TB cases require continuous dosing for at least 6 months of chemotherapy 
leading to poor patient compliance, which further increases the rate of drug resistance (WHO, 
2015). There is a clear need for new anti-tubercular drugs, particularly those that shorten the 
treatment period. However, the long-term and indefinite intracellular survival of 
Mycobacterium tuberculosis in different physiological states has made the development of 
novel therapeutics extremely challenging.  
Cholesterol has been identified as important  in the infection process of M. tuberculosis 
(Crowe et al., 2015; Lovewell et al., 2016; Ouellet et al., 2011; Peyron et al., 2000) and is 
used as a carbon source during survival within macrophages (Pandey et al., 2008; Rohde et 
al., 2012; Van der Geize et al., 2007). In previous work we have demonstrated that an operon 
consisting of hsaA (Rv3567), hsaB (Rv3570), hsaC (Rv3568), hsaD (Rv3569) (Van der 
Geize et al., 2007) is involved in cholesterol metabolism. This operon was first identified in 
M. tuberculosis and also includes the gene encoding arylamine N-acetyltransferase (nat, 
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Rv3566) (Anderton et al., 2006; Payton et al., 2001) and then further characterized in other 
mycobacterial species (Evangelopoulos et al., 2014). It is currently believed that the NAT 
protein may metabolise the alkyl chain generated by cholesterol catabolism (Lack et al., 
2009), whilst the other proteins are involved in the degradation of the sterol nucleus of 
cholesterol (Van der Geize et al., 2007; Griffin et al., 2011; 2012). Studies using transposon 
mutagenesis have shown that HsaC and HsaD are required for the survival of M. tuberculosis 
within macrophages (Rengarajan et al., 2005). The expression of hsaC gene was later 
demonstrated to be essential both in vitro and in vivo for infection of M. tuberculosis in 
guinea pigs (Yam et al., 2009). More recent studies have also implicated a role for the operon 
and HsaD in mycobacterial growth linked to cholesterol catabolism (Griffin et al., 2011). 
HsaD has also been shown to be overexpressed in hypervirulent strains of Mycobacterium 
bovis BCG during mouse infection (Blanco et al 2009) and compounds with antitubercular 
activity have been identified as potential HsaD inhibitors via virtual screening (Rebollo-
Lopez et al., 2015). 
 
HsaD belongs to the superfamily of αβ-hydrolases that consists of the meta-cleavage product 
(MCP) hydrolase subfamily (Lack et al., 2008). HsaD catalyses the hydrolytic cleavage of 
carbon-carbon bonds through a serine protease-like catalytic triad (Lack et al., 2008; Lack et 
al., 2010) of the MCP 4,5-9,10-diseco-3-hydroxy-5,9,17-trioxoandrosta-1(10),2-diene-4-oic 
acid (4,9-DHSA) in the cholesterol metabolism pathway (Van der Geize et al., 2007). In a 
previous study, we demonstrated that mechanism-based serine protease inhibitors can inhibit 
HsaD (Ryan et al., 2014) suggesting that an acyl enzyme intermediate may be formed during 
the reaction process in line with studies on the mechanism of other C-C bond hydrolases 
(Ruzzini et al., 2013; Ruzzini et al., 2012). As the HsaC protein (Yam et al., 2009) is 
unstable in oxygen, HsaD is a promising pharmacological target essential for M. tuberculosis 
infection. It is highly soluble as a stable recombinant protein (Lack et al., 2009) and there are 
multiple crystal structures available (Lack et al., 2008; Lack et al., 2010). Moreover HsaD 
has a very large active site cavity that makes it a good target for fragment based drug 
discovery (FBDD) (Silvestre et al., 2013). FBDD combines NMR, differential scanning 
fluorimetry (DSF) and crystallography to use weakly binding small molecules (<300Da) as 
building blocks to develop potent small molecular inhibitors.  It is firmly established that 
fragment screening is a powerful approach to obtain useful start points for inhibitor 
discovery. Once the biological rationale for a given target is established, then fragment based 
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approaches are warranted as one of the most effective methods to identify tractable start 
points for drug design (Ciulli & Abel, 2007; Ciulli, 2013). This approach has shown 
tremendous success in modern drug discovery (Hudson et al., 2012; Hung et al., 2016) and 
has been particularly recommended for developing agents against tuberculosis (Marchetti et 
al., 2016; Mendes & Blundell, 2016). 
In this study we investigate HsaD as a novel pharmacological target for tuberculosis through 
generation of a specific gene deletion mutant and describe the identification of compounds as 
inhibitors of HsaD by a FBDD approach.  
 
Methods 
Bacterial growth conditions 
M. tuberculosis, M. bovis BCG and Mycobacterium smegmatis mc
2
155 liquid cultures were 
grown in Middlebrook (MB) 7H9 broth containing 10% (v/v) ADC (albumin-dextrose-
catalase), 0.2% (v/v) glycerol and 0.05% (v/v) Tween-80. Mycobacterial strains were also 
grown on MB7H10 agar containing 10% (v/v) OADC (oleic acid-albumin-dextrose-catalase) 
and 0.5% (v/v) glycerol. M. tuberculosis cultures were grown in 10 mL broth in a 30 mL 
vials as standing cultures, M. bovis BCG in 100 mL broth in a roller bottle rolling cultures at 
2 rpm and M. smegmatis in 10 mL in a 50 mL centrifuge tubes rotating at 180 rpm all in a 
37°C incubator, unless specified otherwise. ΔhsaD M. bovis BCG was further supplemented 
with 50 µg/mL hygromycin.  
Growth curve comparison of the wild-type and ΔhsaD M. bovis BCG were done in minimal 
medium containing 0.05% (v/v) tyloxapol and 0.05% (v/v) ethanol with either a) no 
additional carbon source, b) 100 µg/mL glycerol or, c) 100 µg/mL cholesterol. An equivalent 
number of bacteria (6 x 10
8
) were added to start the cultures and the bacterial growth rate was 
measured by monitoring the OD600 daily for 16 days.  
E. coli JM109 cells were grown in Luria-Bertani (LB) broth 10 mL of a centrifuge tube 
rotating at 180 rpm a 37°C incubator. LB agar was used for solid growth of E.coli strains at 
37°C, unless specified otherwise.  
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Generation of the ΔhsaD gene deletion 
Deletion of the hsaD gene was performed using specialised transduction as previously 
described (Bardarov et al., 2002). Briefly, the upstream and downstream flanking DNA 
regions of the hsaD gene were amplified by PCR using the following pair of oligonucleotide 
primers for the upstream flanking DNA region 5’-
TTTTTTTTGCATAAATTGCAGGCACCGTAGGCCAT-3’ and 5’-
TTTTTTTTGCATTTCTTGCAGTGACGTCCATTCAACA-3’ as the forward and reverse 
primers respectively with a BstAPI restriction site (underlined). The primers for the 
downstream flanking region were 5’-
TTTTTTTTCACAGAGTGCTTGACCGAGGCAATTGGAGAC-3’ and 5’-
TTTTTTTTCACCTTGTGCACCTGTTGGGCGGGC-3’ as the forward right and reverse 
primers respectively with a DraIII restriction site (underlined). The upstream and 
downstream products were subsequently digested with DraIII and BstAPI, respectively, and 
ligated with PfIMI-digested p0004s vector arms. The knockout construct was linearised 
following digestion with PacI and cloned into phAE159. Both pAES and phAE159 were 
subsequently digested with PacI, gel purified and ligated with T4 DNA ligase. The ligation 
mixture was then packaged into λ phage heads by in vitro packaging, transduced into E. coli 
and plated on LB agar supplemented with hygromycin. Following validation the phasmids 
were then electroporated into M. smegmatis and grown at a permissive temperature (30°C) to 
generate mycobacteriophages. The resulting high-titre mycobacteriophages were then used to 
transduce the recipient mycobacteria at 37°C (non-permissive temperature). The correct 
identity of loss-of-function mutations was confirmed by PCR amplifications with primers 
against the internal hsaD gene (forward: 5’ AAGTCGGCTCCGGC 3’ reverse: 5’ 
TGGCCGTCGACCAGC 3’) and the region flanking the hsaD deletion (forward: 5’ 
GATGCTCATCTGCCACC 3’ reverse: 5’ ATGACAGCTACCGAGGAAT 3’). 
 
Intracellular survival of ΔhsaD M. bovis BCG in macrophages 
The RAW264.7 mouse macrophage cells were grown as a monolayer in RPMI-1640 media 
(GIBCO, Paisley, UK), supplemented with 1% (w/v) L-glutamine and 10% (v/v) foetal calf 
serum (FCS) at 37°C with 5% CO2. For the intracellular survival assays, RAW264.7 cells 
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were plated approximately 24 hours prior to infection on 6-well plates in the presence of 2 
mL RPMI (supplemented with 10% (v/v) FCS) as described (Bhakta et al., 2004; Westwood 
et al., 2010). Cells were subsequently washed with fresh media, infected with M. bovis BCG 
at a multiplicity of infection of 20 (i.e for every 1 RAW264.7 cell, 20 cells of M. bovis BCG 
were added) and incubated for 2 h. Cells were then washed twice with PBS and re-suspended 
in fresh medium. The medium was later removed and the cells were lysed with 1 mL of 
sterile distilled water for 10 min at 0, 24, 48, 72 and 120 h.  The number of intracellular 
bacteria was determined by serially diluting the lysate, plating it on MB7H10 agar plates and 
incubating at 37°C for 3-4 weeks.  
 
Effect of inhibitors against M. tuberculosis grown in cholesterol 
The minimum inhibitory concentrations (MIC) of selected inhibitors, were determined using 
the spot culture growth inhibition assay (SPOTi). This method has been compared favourably 
with other methods of MIC determination (Evangelopoulos & Bhakta, 2010). Briefly, 
mycobacteria were plated in 24 well plates on minimal agar based media containing: 
asparagine (0.5 g/L), KH2PO4 (1.0 g/L), Na2HPO4 (2.5 g/L), ferric ammonium citrate (50 
mg/L), MgSO4,7H2O (0.5 g/L), CaCl2 (0.5 mg/L), ZnSO4 (0.1 mg/L), agar (1.5% w/v) and 
either glycerol (0.1% v/v) or cholesterol (0.01% w/v). Fragments dissolved in DMSO (0.0125 
µg/mL, 0.025 µg/mL, 0.05 µg/mL, 0.1 µg/mL, and 0.2 µg/mL) or DMSO alone were mixed 
with 2 mL of the minimal media with cholesterol per well. The final DMSO concentration in 
the wells containing fragments was 0.2%. In addition a well with 0.2% DMSO only as well 
as isoniazid at various concentrations (0.001 µg/mL, 0.01 µg/mL, 0.1 µg/mL, 1 µg/mL and 
10 µg/mL) were used as positive controls. The inhibitors and  isoniazid  were prepared by 
one experimentalist and supplied as a numbered array such that growth experiments were 
carried out blinded.   The plates were then inoculated with 2 µL (approximately 10
3
 viable 
cells) of a mid-log phase culture of either M. bovis BCG or M. tuberculosis that was added in 
the centre of each well and allowed to soak before the plates were sealed with para-film, 
wrapped with aluminium foil and incubated at 37°C for 2 weeks until a spot of colonies were 
developed in the control wells. The MIC was determined as the lowest concentration in wells 
where mycobacterial growth was not evident. This was repeated in triplicate in three 
independent experiments and the same MIC values  were obtained in all experiments. 
Effect of inhibitors against E. coli  
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An overnight culture of E. coli JM109 cells grown as stated before was diluted in LB media 
to a final OD600 of 0.1 and acted as a working culture. 10µL of this working culture was used 
to inoculate a 96 well plate containing 90µL of LB media with a range of inhibitor 
concentrations up to 100 µg/mL. The maximum DMSO concentration in the well was 1.7% 
(v/v). The plates were then transferred into the Tecan M200 Infinite Pro spectrophotometer 
where they grew at 37°C as standing cultures with absorbance measurements at 600nm  taken 
every hour for 4 hours 
Cytotoxicity against mammalian cells 
Cytotoxicity was tested using CCL-228 colorectal cancer cells (American Tissue Culture 
Collection Manassas, VA). Cells were cultured in Dulbecco’s Minimum Essential Medium 
(GIBCO, UK), supplemented with 10% (v/v) foetal bovine serum (FBS; Sigma-Aldrich, 
Poole, UK), 10,000U penicillin, 10 mg/mL streptomycin in 0.9% NaCl (Sigma-Aldrich), and 
maintained at 37°C in a humidified atmosphere with 5% CO2. Cells were seeded in 96-well 
plates (20,000 cells/well) and treated for 48 h after which they were incubated with 100µL of 
50µg/mL MTT solution in phenol red free DMEM (GIBCO) for 3 h in the dark at 37°C. The 
MTT was removed and the crystals solubilised with 100µL DMSO for 15 min at room 
temperature with gentle shaking. The intensity was measured colorimetrically at 570 nm 
using the M200 Infinite Pro plate reader (Tecan) and percent growth was calculated. 
Thesestudies were carried out blind by one experimenter (EP) using numbered samples 
provided by AR with the numbers randomised in 5 separate experiments. 
Fragment based drug discovery 
Differential scanning fluorimetry (DSF) was performed on a total of 1258 fragments as 
described previously (Niesen et al., 2007), using 0.4-1 µM HsaD in the presence of 2.5 
SYPRO orange (Invitrogen) and 2.5 mM of compound (0.5 µL from a 0.1 M stock) at a final 
volume of 100 µL per well (final dmso concentration of 2.5%) in 50 mM HEPES 300 mM 
NaCl pH 7.5. Fluorescence was monitored using an Agilent Mx3005p qPCR instrument 
(Santa Clara, USA). The fluorescence excitation and emission wavelengths were 483 and 533 
nm. The output data was plotted as derivative of the fluorescence versus temperature, and the 
maximum of such derivative over temperature was determined as the melting temperature 
(TM). The primary DSF screen was carried out three times in triplicate and the repeat screen 
was also carried out three times in triplicate making a total of six independent determinations 
in triplicate for each compound identified as a hit. Hits were identified by the shift in TM 
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compared to HsaD with vehicle according to previously described methodologies (Cuilli, 
2013.  
NMR fragment screening 
Confirmed hits were validated by ligand-observed NMR spectroscopy (Ciulli et al., 2007; 
Dalvit et al., 2001; Ferguson et al., 2013). All NMR experiments were carried out at 278 K 
on a Bruker Avance 700 MHz equipped with a 5 mm triple TXI cryoprobe with z gradients. 
Relaxation‐edited NMR experiments incorporated a CPMG spin-lock time of 200 ms before 
the acquisition period (Carr & Purcell, 1954). . Saturation Transfer Difference (STD) NMR 
experiments employed a 40 ms selective Gaussian 180° shaped pulse at a frequency 
alternating between ‘on resonance’ (0.5 ppm) and ‘off resonance’ (~80 ppm) after every scan 
(Mayer & Meyer, 1999). Water suppression was achieved by using a W5 Watergate gradient 
spin-echo pulse sequence (Piotto et al., 1992). WaterLOGSY experiments (Dalvit et al., 
2000; 2001) employed a 20 ms selective Gaussian 180° shaped pulse at the water frequency 
and an NOE mixing time of 1 s. Water suppression was achieved using a double‐gradient 
echo excitation sculpting sequence with gradients. The resulting spectra were analyzed using 
Topspin 2.0 software (Bruker). All samples were made up to a total volume of 200 μL in 3 
mm capillaries, and contained 1.2 mM fragment, 50 mM Tris-HCl buffer at pH 7.5, 10% v/v 
D2O, and 2.4% v/v DMSO-d6. (Trimethylsilyl)-propionic acid-d4 (TSP) was present at 20 μM 
concentration in all samples for calibration purposes. A protein only control sample was run 
as buffer control. Each fragment was run as 3 samples – (A-C). A) Fragment only; B) 
Fragment + protein (10 μM HsaD); C) Fragment +HsaD + displacer compound PMSF (100 
μM).  
 
Enzymatic assays  
Following the initial identification of fragments from the fragment based drug design library, 
inhibition assays were carried out as previously described (Ryan et al., 2014) in the presence 
of 1 mM with compounds 1-7. Subsequently, compounds that were capable of inhibiting the 
cleavage of HOPDA by HsaD, were further selected for IC50 determination using a range of 
concentrations (1 mM, 0.5 mM, 0.375 mM, 0.25 mM, 0.125 mM, 0.05 mM and 0 mM or 3.5 
mM, 3 mM, 2.5 mM, 2 mM, 1.5 mM, 1 mM, 0.5 mM and 0 mM). Briefly pure HsaD (16 
µg/mL in 100 mM phosphate buffer pH 7.5, 20 mM NaCl) was added to the reaction mixture 
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in the presence of 100 µM HOPDA (final concentration of 1% ethanol v/v) and inhibitor 
(final DMSO concentration of 5%) in a final volume of 100 µL. The enzymatic activity was 
measured by monitoring the absorbance at 450 nm at 21°C using a M200 Infinite Pro plate 
reader (Tecan) and the IC50 was determined using GraphPad Prism. The ε450 of HOPDA was 
measured as 13,200 M
-1
cm
-1
. N values refer to the number of independent experiments. 
 
Solution of the structures of HsaD with Fragments 2, 27 and 32 
Crystals of apo-HsaD were grown as described previously (Lack et al., 2008). All fragments 
were dissolved directly into the cryoprotectant containing 30% (w/v) PEG-3000, 0.1 M 
CHES pH 9.5, 25% (v/v) glycerol, at concentrations of between 15 mM and 50 mM. Crystals 
were transferred into the cryoprotectant containing one of the fragments and allowed to soak 
overnight at 21°C before flash freezing for analysis.  
Data collection for the structures of HsaD bound to 2, 27 and 32 were all performed at the 
Diamond Light source (Oxon, UK) using beamline I24 in the case of the structure with 2 and 
using beamline I03 for the others. In all cases initial processing was performed via Xia2 
(Winter, 2010) using XDS (Kabsch, 2010) to index and either Scala (2) (Evans, 2006) or 
Aimless (Collaborative Computational Project, 1994; Winn et al., 2011) (27 and 32), to 
merge and scale the data. The structure was solved via molecular replacement using 
PHASER (McCoy et al., 2007) using the structure of apo-HsaD (PDB code, 2vf2) (Lack et 
al., 2008) stripped of all ligands as a search model. The atomic models were rebuilt in COOT 
(Emsley et al., 2010) and refined using REFMAC (Murshudov et al., 1997) and PHENIX 
(Adams et al., 2010). Model restraints for 2, 27 and 32 were generated in eLBOW (Moriarty 
et al., 2009).  
Data and Statistical analysis 
The data and statistical analysis comply with the recommendations on experimental design 
and analysis in pharmacology (Curtis et al., 2015). Samples were randomised in all 96 well 
experiments and sample identity was not known to the investigator. Data is shown as the 
mean plus or minus the standard deviation and IC50 values in enzymic inhibition assays were 
determined via non-linear fit analysis in Graphpad Prism.  
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Software tools  to fit  raw data obtained from differential scanning fluorimetry  for data 
visualization and analysis were used based on Microsoft Excel  and were  obtained  from the 
Structural Genomics Consortium Oxford (ftp://ftp.sgc.ox.ac.uk/pub/biophysics), see also 
(Niesen et al 2007). The entire fluorescence raw data (RFU) from the thermal melt curve was 
accurately fitted to a Maxwell-Boltzman distribution in Graphpad Prism.  
Materials 
All reagents were purchased from Sigma Aldrich (Poole, UK) unless otherwise stated. 3,5-
dichlorobenzenesulphonamide, 3-chloro-4-hydroxybenzoate, 4-toluenesulphonamide and 2-
oxovaleric acid were obtained from TCI Europe. 3,5-diflurobenzenesulphonamide, 3,5-
dichlorobenzamide and 3-bromobenzenesulphonamide were obtained from Apollo Scientific 
and ethyl-3,5–dichloro-4-hydroxybenzoate was obtained from Maybridge. The fragment 
library used in this study was composed of 1258 compounds from commercial libraries 
supplied by Maybridge (Thermo Fisher Scientific: http://www.maybridge.com/), as 
previously described (Ciulli, 2013; Van Molle et al., 2012). All library compounds were 
dissolved and stored in d6-DMSO.  
 
All inhibitors were dissolved in DMSO. The DMSO final concentration in the assays was 5% 
(v/v) for the enzymatic assays and between 0.02% and 1.7% (v/v) for the growth 
experiments. The synthetic substrate, 2-hydroxy-6-oxo-6-phenylhexa-2,4-dienoic acid 
(HOPDA) was synthesised by Almac Sciences (Craigavon, Northern Ireland) as previously 
described and dissolved in ethanol (1% v/v) (Lack et al., 2009). The fragment library was 
prepared as previously described (Ciulli, 2013; Van Molle et al., 2012).  
 
Results  
Growth 
Deletion of hsaD in M. bovis BCG (ΔhsaD) was generated using a mycobacteriophage-based 
knockout method (Bardarov et al., 2002). All of the hygromycin resistant colonies tested 
were the correct mutant. Our results are in accordance with previous studies, which have 
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reported that approximately 95% of antibiotic-resistant transductants were the correct 
genotype (Bardarov et al., 2002).  
When grown in MB7H9 broth (Figure 1A) or in minimal medium (Figure 1B) the deletion of 
hsaD had no apparent effect on bacterial growth when compared with M. bovis BCG. 
However, when the minimal medium was supplemented with cholesterol (Figure 1C), a 
significant difference between the two strains was observed. Whilst the growth of the wild 
type strain was very similar to that in minimal medium alone, the growth of ΔhsaD M. bovis 
BCG was significantly inhibited in the presence of cholesterol as compared to M. bovis BCG 
(Figures 1B & C). The growth of ΔhsaD M. bovis BCG in the presence of cholesterol was 
suppressed compared with growth in minimal medium alone.  
Growth in minimal medium with glycerol as the sole carbon source is supported in both the 
ΔhsaD strain and M bovis BCG. The gene deleted strain showed a slight lag in rate of growth 
although it caught up by day 16, reaching the same optical density (OD600 = 1.5) (Figure 1D).  
The intracellular survival of the wildtype and ΔhsaD strains of M. bovis BCG within 
RAW246.7 shows that, similar to ΔhsaC and Δnat strains, there was a reduction in 
intracellular growth of the ΔhsaD strain as compared to  M. bovis BCG (Figure 1E). 
We also deleted hsaD  from M. smegmatis and when it was grown on cholesterol as carbon 
source the culture turned pink .(Supplementary Figure 1) . 
Identification of chemical fragments as inhibitors of HsaD 
A commercial library of rule-of-three compliant 1258 fragments (Silvestre et al., 2013) was 
screened by DSF. The melting temperature of pure recombinant HsaD was monitored in the 
presence of the fragments. The melting temperature of HsaD in previous studies (Lack et al., 
2009) had been determined by circular dichroism and loss of enzymatic activity of the protein 
itself to be between 69 and 72
o
C. The high melting temperature was confirmed by DSF 
monitored by SYPRO Orange to be 72.7 (average mean value from quadruplicates across 17 
plates) +/- 0.21
o
C (average SD from quadruplicates across 17 plates) in the presence of 
solvent and no added fragment. Fragments were identified as potential binders to purified 
HsaD when a shift was monitored in the melting temperature of greater than two standard 
deviations from the mean melting temperature of pure HsaD alone (Table 1). Hit compounds 
(18) from the primary screen were re-tested in duplicates in the thermal shift assay, from 
which 8 were confirmed. The validated fragments were also tested as inhibitors of HsaD at a 
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concentration of 1 mM of the compound (Figure 2) and were in addition tested by saturation 
transfer NMR for displacement by PMSF, an already identified inhibitor (Ryan et al., 2014) 
(Table 1 & Figure 2A).   
From this combination of methods, a series of seven distinct fragments were identified as 
binders. Fragment 1 was not pursued further due to its insolubility at 1 mM. In addition to the 
“hits” from the screen, a selection of 20 compounds from the library which showed no 
evidence of binding by the DSF criteria, were also tested at 1 mM as inhibitors of HsaD and 
none were found to inhibit the enzyme (Data not shown) . From the initial inhibition studies 
at 1 mM, two compounds looked promising - compound 2 and compound 6, which produced 
38 % and 60% inhibition respectively (Figure 2). Fragment 2 is a sulphonamide and fragment 
6 is a hydroxybenzoate. 
When tested at a range of concentrations, compound 2 (3,5-dichlorobenzenesulfonamide) is 
an inhibitor of HsaD with an IC50 of 0.41 mM (Table 2) and fragment 6 (ethyl 3,5-dichloro-4-
hydroxybenzoate), despite it not being displaced by PMSF (Table 1) , is also an inhibitor of 
HsaD with an IC50 of 0.52 mM (Table 2). 
The fragments which were identified were distinct from previously identified substrates 
(Lack et al., 2010) and also distinct from putative inhibitors identified from a virtual screen 
(Rebollo-Lopez et al., 2015) but interestingly bear some resemblance to the central moiety of 
an inhibitor identified as targeting the HsaAB protein complex of the same operon 
(Vanderven et al, 2015).  
A small series of compounds related to each of the two classes of hit fragments 2 and 6 was 
tested for inhibition of HsaD (Supplementary table 1). 
Derivatives of fragment 2 as inhibitors of HsaD 
We investigated the small series of fragments modified around Compound 2 which has two 
chlorine atoms at the meta position. We investigated the effects of altering the position and 
number of chlorines in the molecule as well as substituting different halide groups. Removal 
of one chlorine from position 3 (Compound 9) was detrimental to the inhibitory potency and 
the IC50 was increased more than 10 fold to 5 mM (Supplementary table 1). Removal of both 
the chlorine atoms as in compound 8 (Table 1 supplementary & Table 2), destroyed 
inhibition of HsaD completely. Substitution of the chlorines by fluorine (Fragment 10) also 
resulted in loss of inhibition of HsaD (Table 1 Supplementary).Having a single chlorine in 
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the para position (Fragment 13) did not possess any inhibitory effects on HsaD 
(Supplementary Table 1).  
Altering the position of chlorine from meta to the ortho position (Fragment 11) likewise 
resulted in a decreased inhibitory effect (IC50 1.89 mM) compared with fragment 2 and 
changing the chlorines to trifluoromethyl compounds (fragment 12) showed poorer inhibition 
as compared to the initial compound with less than 50% inhibition being reached. 
(Supplementary Table 1). Mono-substituted benzenesulfonamides with a bromine in position 
3 (Fragment 14), like the mono-chlorinated fragment, produced a similar IC50 of 2.69 mM.  
The library of fragments used for these studies also incorporated sulphonamide fragments 
with the addition of nitro-, amino-, methyl-, methoxy-, hydroxy-, and carboxy- groups on 
various positions of the benzene ring. None of the modifications including these side groups 
were capable of inhibiting HsaD (Fragments 15-23) with the exception of Fragment 20 
which, with an IC50 of 92.6 mM, was an extremely poor inhibitor.  
A derivative of Fragment 2, 3,5-dichlorosulfanilamide in which an amide group was 
incorporated in position 4 of the benzene ring, was able to inhibit HsaD with an IC50 of 0.16 
mM (Fragment 24) (Table 2 and Supplementary Table 1). Addition of a dimethyl group on 
the nitrogen (Fragment 25), however reduced the inhibitory effect on HsaD with an IC50 of 
3.68 mM. Replacement of the chlorines with bromines (Fragment 26) reduced the inhibitory 
potency compared with the parent compound to IC50 2.10 mM.  
The important features for inhibition of HsaD by derivatives of 2 appear to be a para 
hydroxyl group on the aromatic  ring and two chlorines as meta substituents and the 
inhibitory potency (IC50 of 0.27mM) of fragment 27 supports this conclusion. Fragment 27 
also has a sulfonate group at position 1 (Table 2).  
Derivatives of compound 6 as inhibitors of HsaD 
A small group of hydroxybenzoate analogues were tested for comparison with compound 6 
as inhibitors of HsaD.  
Like compound 2, compound 6 has meta (3,5) substituted chlorine atoms and the position and 
number of chlorine substituents on the aromatic ring was altered as well as the presence of 
the 4-hydroxyl group. 
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Ethyl 3,5-dichloro-4-hydroxybenzoate (Fragment 6) inhibited HsaD (IC50 0.52 mM). When 
the hydroxyl group was removed there was no inhibition of HsaD (Fragment 28) and when 
either one or both of the chlorine atoms were removed no inhibition was then observed. 
Fragment 29 with only one chlorine at the 3 position was not inhibitory and the same was 
true when both chlorines were missing (Compound 30).  
An analogue in which both the chlorines are present and the 4 hydroxyl is present but there is 
a change in the ester substituent on the 1 position to a carboxylate group (3,5-dichloro-4-
hydroxybenzoic acid - Fragment 32) has the same IC50 value of 0.54 mM as the parent 
compound (Table 2B and Supplementary table 1). If the hydroxyl group in this charged 
compound is substituted by an amino group (fragment 33), the IC50 remains essentially the 
same (0.55 mM). Interestingly, altering the ethyl substituent on the carboxylate group to a 
methyl group (compound 31) was inhibitory but with a slightly higher IC50 (0.71 mM).  
To further elucidate the importance of the chlorines on positions 3 and 5, these were 
rearranged into positions 1 and 3 with the addition of a nitro group in position 6 (Fragment 
35). The resulting compound was less inhibitory, with an IC50 of 2.15 mM. Removal of the 
chlorines and only the presence of the carboxylic acid and amine group in positions 1 and 4 
of the benzene ring respectively (Fragment 36) and the amine in position 3 (Fragment 37), 
completely reversed the inhibitory effect (supplementary Table 1). 
Structural studies of HsaD with inhibitors 
In order to identify the mode of binding of the inhibitors which were identified, structural 
studies were carried out using three different inhibitors : Compound 2 (IC50, 0.52mM) and an 
analogue (compound 27, IC50, 0.27mM) were chosen as representatives of the sulphonamide 
series and compound 32 (IC50, 0.54mM) was chosen as a representative of the 
hydroxybenzoate class. The latter compound was chosen in preference to the parent 
compound because it is more soluble. Crystals of HsaD were soaked with the inhibitory 
fragments.  
The crystal structure of HsaD with compound 2, was obtained to a resolution of 2.1 Å. The 
crystal structure with 3,5-dichloro-4-hydroxybenzenesulphonic acid (fragment 27) was 
obtained at a resolution of 2.68 Å and the structure of HsaD was also obtained where the 
ligand bound was a derivative of hydroxybenzoic acid ( 3,5-dichloro-4-hydroxybenzoic acid 
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Fragment  32), at a resolution of 2.27 Å. Processing and refinement statistics for all three 
structures are shown in table 3. 
The crystal structures of each of these ligand bound structures can be compared with the 
structure of HsaD alone (Figure 3A). With the exception of a 55° rotation of the side chain of 
Trp270, which is only observed in the structure of HsaD with compound 2, there are no major 
conformational changes compared with structure of apo-HsaD (overall RMSD 0.2 - Figure 
3). The binding of substrate molecules to HsaD revealed the presence of two different 
conformations, an open conformation for the apo-enzyme and a closed conformation when 
the substrate was bound. However, there was no change in the juxtaposition of the active site 
residues in the main catalytic pocket. The same is true on the binding of the inhibitors which 
have been investigated here (Figure 3A).  
Two molecules of fragments 2 and 27 were observed bound to HsaD, in their respective 
structures: one molecule was bound in each of the active sites of the protomers in the dimer 
in the asymmetric unit. In each of these cases the orientation of the ligand was 
superimposable with its orientation in each of the two active sites in the dimer. 
Compound 32 was found in only one of the active sites of the dimer in the asymmetric unit, 
with the A chain active site being unoccupied. This reflects the data obtained with the 
substrate bound structures (Lack et al., 2010). The inhibitor binding sites each overlap with 
the binding site of the substrate from previous structures (Figure 4D) and are close to the 
active site Ser (Fig 3B-D). These structural studies confirm the specificity of the screening 
process in identifying inhibitors of HsaD.  
Binding of 2 and its analogue 27 to HsaD 
The structure of HsaD bound to fragment 2 allowed the unambiguous determination of the 
fragment’s binding orientation. Fragment 2 binds within the active site with its sulphonamide 
group making short-range hydrogen bonds with the side chain of Asn244 (Figure 3B). It also 
forms a hydrogen bond with the backbone amide of Gly140 and a water bridged interaction 
with the side chain of Asn89. The benzene ring forms hydrophobic contacts with Gly46 and 
the side chains of Leu115, Leu158 and Val243. One chlorine forms contacts with the side 
chains of Met208 and Phe220, while the other contacts the side chains of Phe173 and His269.  
The number of hydrophobic contacts made by the chlorines explains why removal of one or 
both has a detrimental effect on fragment binding (Fragments 8 and 9) and also why 
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replacement of the chlorines with polar functional groups is energetically unfavourable 
Fragments (16, 18, 20). The importance of the interactions of chlorines at positions 3 and 5 
also explains the inability of 17, 21 and 22 to inhibit HsaD. The hydrophobic contacts with 
Met208 and Phe220 are relatively long range (4.3 Å and 4.8 Å respectively) which indicates 
why the bromine of the inhibitory fragment 14 could be accommodated.  
The short-range hydrogen bond formed by the sulphonamide nitrogen explains the 
detrimental effect observed by double methylation of this group in fragment 25. 
Accommodation of the sulphanilamide of 24 in the current orientation would not be possible 
due to the distance between the fragment’s ring and Gly46 being too short to allow 
accommodation of an amine group in between (3.7 Å).  
Fragment 27 binds with its acidic group at the entrance of the polar sub-pocket (Fig 3C) that 
binds the dienoate moieties of HOPDA and 4,9-DHSA (Lack et al., 2010). The sulphonate 
group of 27 forms hydrogen bonds with the side chain of Trp270 as well as the backbone 
amides of Gly45 and Gly46 (Figure 3C). The sulphonate also forms a salt bridge interaction 
with the side chain of Arg192 (4.5 Å). One of the chlorines of 27 fits into a hydrophobic 
pocket formed by the side chains of Leu158, Phe173, Met177 and Val243 (all distances 
<4Å). The other chlorine interacts with Gly45 and the side chain of Leu115. 
The acidic compound 27, binds in a different orientation to the uncharged sulphonamide 2 
(Figure 4B). The charged sulphonate group of 27 may drive its binding to the polar pocket of 
the active site where it is able to form the salt bridge with Arg192 that could not be formed 
with the neutral sulphonamide of 2. This clear distinction in the binding modes of fragments 
that have charged versus simply polar groups provides useful information for modifying the 
fragments to improve affinity.  
Binding of fragment 32 to HsaD 
Fragment 32 binds in an almost coplanar conformation to 27 (Figure 3D). However, its 
binding position is shifted by around 1.8 Å outward from the polar sub-site (Figure 4). As a 
result, the carboxyl group of 32 is not inserted as far into the pocket as the sulphonate of 27. 
The carboxyl group forms hydrogen bonds with the side chain of Ser114 and the backbone 
amides of Gly45 and Gly46 (Figure 3D). This also means the fragment is unlikely to form a 
salt bridge with Arg192 (separation >6 Å). The altered binding conformation also removes 
the interaction of the chlorine with Gly45, leaving only the contact with Leu115. The other 
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chlorine still contacts Leu158, Phe173 and Val243 but does not contact Met177, rather, it 
interacts with Val155. 
The extensive hydrophobic contacts made by both chlorines of 32, explains their importance 
in the binding of the fragment. In view of the proposed importance for the 4-hydroxy group 
of 32 in the inhibition of HsaD, it was unexpected to find the hydroxyl  group makes no 
interactions with either the side chain or backbone of HsaD.  
The binding of 32 (Figure 3D), like the other acidic inhibitor investigated (27 Figure 3C) 
shows a distinct binding orientation from the uncharged sulphonamide (fragment 2) Figure 
3B. 
From these comparisons of binding sites, using fragment 2 as a starting point (Figure 4) there 
are two possible areas of expansion, the first is into the polar pocket that is accessed by the 
acidic groups of 27 and 32 (Figure 4C). The second area of expansion would be into the 
strongly negatively pocket in close proximity to the sulphonamide group of 2. Expansion into 
this polar pocket would mimic that of HOPDA (Figure 4D) which extends deep into the 
pocket and makes shorter range salt bridge with Arg192 (3.1 Å). 
 
 
Effects of inhibitors on growth of M. bovis BCG and M. tuberculosis H37Rv. 
In order to evaluate the specific anti-mycobacterial activity of the compounds, we tested them 
for inhibition of growth of E. coli. There was no inhibition observed at up to 100 μg/mL 
(Supplementary Figure 2). We also tested for any cytotoxic effect against RAW264.7 murine 
macrophage cells and again found no evidence of eukaryotic cell toxicity at concentrations up 
to 100 μg/mL (data not shown).  
None of the HsaD inhibitors had any effect on the growth of M. bovis BCG or M. 
tuberculosis when cultured in enriched MB7H9 broth. This observation is consistent with the 
effect seen in the gene deleted mutant strains. In order to test the proof of principle that 
inhibitors of HsaD would have an effect on the growth of M bovis BCG and M. tuberculosis 
on cholesterol, we tested the fragments at concentrations ranging from 12.5 µg/mL to 200 
µg/mL in minimal growth media supplemented with cholesterol, using the SPOTi assay. 
Fragment 6 which is one of the most potent inhibitors of HsaD was also the most effective at 
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inhibiting growth of both M. bovis BCG and M. tuberculosis in the presence of cholesterol, 
with growth only at 12.5 µg/mL. On the other hand, fragment 8 which showed no inhibition 
of HsaD was also ineffective at concentrations up to 200 μg/mL in inhibiting the growth of 
either M. bovis BCG or M. tuberculosis on cholesterol.  
Fragment 2 was capable of inhibiting the growth of M. bovis BCG cells with an MIC of 
<12.5 µg/mL whilst fragment 24, inhibit the growth at 25 µg/ml. Fragment 27 on the other 
hand, did not appear to have an effect, with growth evident even at the highest concentration 
(200 µg/mL). As with fragment 2, both fragments 6 and 32, completely halted growth, with 
an MIC below 12.5 µg/mL. Isoniazid, gave an MIC of 0.1 mg/mL on bacteria grown on 
cholesterol.  
Similarly, the effect on M. tuberculosis growth following treatment with the fragments was 
also investigated during growth on cholesterol. Treatment with fragments 2 and 6 gave an 
MIC of 50 µg/mL and 25 µg/mL respectively, whilst fragments 24 and 32, 200µg/mL. No 
inhibition was observed with fragments 27 and 8 (growth present at 200 µg/mL) therefore, 
the MIC could not be calculated. Isoniazid was again found to have an MIC of 0.1 mg/mL. 
Fragment 27 is negatively charged and is ineffective in the inhibition of growth (see 
discussion below).   
Discussion  and Conclusions 
We have  investigated the role of hsaD in mycobacteria and  determined whether the gene 
product is a suitable target for developing anti-tuberculars using a fragment based approach 
to identifying inhibitors of the HsaD enzyme. We have confirmed effects on growth of 
deleting the hsaD gene and used structural studies to demonstrate the binding of inhibitors 
identified by this method. We have also demonstrated that inhibitors of the enzyme  inhibit 
the growth of M. tuberculosis on cholesterol. 
 
Role of HsaD in growth 
There is growing evidence from whole genome studies of the importance of cholesterol for 
intracellular survival of M. tuberculosis and recurring evidence for the importance of the 
operon encoding HsaD as being essential for intracellular survival of M. tuberculosis and M. 
bovis BCG. We show here that this is the case in studies where we have created a targeted 
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deletion of hsaD from M. bovis BCG. We demonstrate that the growth of hsaD M. bovis 
BCG on miminmal medium plus cholesterol is inhibited (Fig. 1C).   
In addition to the effects on the growth pattern of the hsaD M. bovis BCG strain on 
cholesterol, we also generated a hsaD strain of M. smegmatis and we observed a pink colour 
when the latter strain was grown on minimal medium plus cholesterol in liquid culture 
(supplementary Fig. 1. )  The same observation has been made when a ΔhsaC M. tuberculosis 
H37Rv strain is grown in minimal medium with cholesterol (Yam et al., 2009). Therefore, 
similar to the “pink” metabolite of the ΔhsaC M. tuberculosis we propose that deletion of 
hsaD results in inhibition of growth of M. bovis BCG on cholesterol as a result of 
accumulation of an inhibitory metabolite.  
In addition to effects on growth on cholesterol, we have also noted a lag in growth on 
glycerol in minimal medium of the ΔhsaD strain (Fig. 1D). This mirrors previous findings on 
deletion of hsaD and other essential genes involved in cholesterol catabolism from M. 
tuberculosis (Griffin et al., 2011).  Additionally it has been observed that hsaD expression is 
significantly increased in M. smegmatis when grown on cholesterol (Uhía et al., 2012) and 
genome wide studies with M. smegmatis grown on cholesterol have also pointed to an 
increase in HsaD expression on growth on cholesterol (Li et al., 2016). 
We have also investigated growth in macrophages. Whole genome studies have previously 
identified the role of HsaD in the survival of M. tuberculosis within macrophages (Sassetti et 
al., 2003). It has also been demonstrated that other genes in the operon (hsaC and nat) are 
essential for survival of M. bovis BCG in macrophage (Anderton et al., 2006; Bhakta et al., 
2004).  
Similar to ΔhsaC and Δnat strains, there was a reduction in intracellular growth of the ΔhsaD 
strain as compared to the M. bovis BCG (Fig. 1E). This is consistent with the whole genome 
studies and studies identifying the role of other members of this operon in the metabolism of 
cholesterol, which has been identified as controlled as the Kst-Regulon (Kendall et al., 2007; 
Kendall et al., 2007; Uhia et al., 2012)).  
Identification of chemical fragments as inhibitors of HsaD 
The studies described above add to the growing weight of evidence that the operon in which 
hsaD is encoded along with the nat gene in the same gene cluster (Anderton et al., 2006) are 
  
This article is protected by copyright. All rights reserved. 
essential for intracellular survival of mycobacteria and also that the gene product are required 
for cholesterol metabolism in M. bovis BCG and M. tuberculosis (Kendall et al., 2010; Van 
der Geize et al., 2007; Yam et al., 2009). Given this importance, we speculated that the hsaD 
gene is a potential target for anti-tubercular agents. Supporting drug design, the crystal 
structure of HsaD has been established to better than 2 Å resolution with the substrate 
HOPDA bound and shows that the active site cleft is over 2100 Å
3
, which is a good prospect 
for a fragment based approach to identifying inhibitors (Lack et al., 2008). HsaD is also a 
stable soluble protein which crystallises readily (Ryan et al., 2014). Moreover, chemical 
inhibitors of HsaAB were found to dramatically decrease the intracellular proliferation of M. 
tuberculosis in macrophages (VanderVen et al., 2015). 
Fragment based drug discovery relies on having crystallographic data. The structure of HsaD 
has been determined alone (Lack et al., 2008) to 2.6 Å and the structure of an inactive S114A 
mutant of HsaD   has been determined at resolutions of better than 2 Å with one of several 
different substrates bound (Lack et al., 2010). It was necessary to use the inactive version of 
HsaD in order for the substrate/protein complex to be stable enough for crystallisation. In 
each of the crystal structures, the asymmetric unit consists of two protomers of identical 
polypeptide chains with one protomer being assigned as the A chain and the other as the B 
chain. These protomers are identical and each folds to form an α/β hydrolase fold which 
contains an active site including the catalytic triad (Ser114, His269 and Asp241). (Lack et al., 
2008; Lack et al., 2010).  
We used a medium throughput platform for screening a well-defined fragment library (Cuilli 
2007, 2013) and following subsequent enzyme inhibition studies we identified two fragments 
namely  compound 2 (3,5-dichlorobenzenesulfonamide)  and fragment 6 (ethyl 3,5-dichloro-
4-hydroxybenzoate), (Table 2) which each have IC50 values of less than 1mM. We 
investigated these compounds and a series of chemical derivatives by both enzymological 
methods and by determining their crystallographic structures to identify the binding mode. In 
addition we determined their effects on growth of mycobacteria and E. coli for comparison 
and this is discussed below.  
From the series of compounds which we tested, we were able to identify key features of 
fragment 2 and fragment 6 which were important for inhibition. The important features for 
inhibition of HsaD by derivatives of 2 appear to be the introduction of  a para hydroxyl group 
on the aromatic  ring and the presence of two chlorines as meta substituents and the inhibitory 
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potency (IC50 of 0.27mM) of fragment 27 supports this conclusion. The potency of 
derivatives of fragment 6 support the conclusion that the presence of chlorine substituents on 
the ring at the meta positions and the presence of a hydroxyl at the para position are 
important features for inhibition of HsaD.  
We obtained the crystal structures of HsaD with compound 2 and a derivative, compound 27,  
bound. The structure of HsaD with compound 6 could not be determined but we obtained a 
high resolution structure of HsaD with compound 32 bound. Compound 32 is a derivative of  
our hit fragment 6.  
Compound 27, a sulphonate, and compound 32, a carboxylate, bind to HsaD in a very similar 
orientation (Fig. 4A) which is distinct from, but overlapping with, the binding site of 
Compound 2, an uncharged but polar sulphonamide (Fig. 4B). Specifically, the negatively 
charged moieties bind in the section of the active site pocket which was identified as the polar 
sub pocket which accommodates the negatively charged section of each of the negatively 
charged substrates. including its physiological substrate from cholesterol degradation (Lack 
et al., 2010).  
Whilst each of these inhibitory compounds is bound in the active site, the adjacent nature of 
these binding sites provides an excellent starting point for growth into new areas of the active 
site pocket which is a key feature of fragment based drug development (Mancetti et al., 2016. 
We have also tested these compounds identified from the screen and their derivatives as 
inhibitors of growth of E. coli, M. bovis BCG and M. tuberculosis. None of the compounds 
inhibited growth of E. coli at 100 µg/mL (Supplementary Fig 2). In addition, the compounds 
were found to be non-cytotoxic.  Inhibition of growth of both M. bovis and M. tuberculosis 
on cholesterol was observed and the potency of inhibition of enzymic activity broadly 
mirrored the effects on growth. This was the case apart from the potent and negatively 
charged derivative of compound 2, namely compound 27. Its ineffectiveness in the whole-cell 
inhibition may possibly be due to a lack of permeation through the lipid-rich mycobacterial 
cell-wall.  
We conclude that HsaD is a valid target for antitubercular drug discovery.  In view of the 
growing threat of multi drug resistant tuberculosis no viable target which has characteristics 
like HsaD should be ignored.  
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Table 1 
Compound TM 
shifts* 
NMR PMSF displacement Structure 
 1 1.78; 
2.64; 
2.64 
Hit Displaced 
 
2 0.77; 
0.38; 
0.38 
Hit Displaced 
 
3 0.55; 
0.76; 
0.76 
Hit Displaced 
 
4 0.55;  
-2.26;  
-2.26 
Hit Displaced 
 
5 0.92; 
1.13; 
1.13 
Hit Not displaced  
(PMSF bound) 
 
6 0.70; 
1.13; 
1.13 
Hit Not displaced  
(PMSF not bound) 
 
7 0.82; 
0.38; 
0.76 
Hit Displaced 
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Table 1. Fragments from a 1258 member library producing a significant shift in HsaD TM. and 
where saturation NMR demonstrated displacement of the ligand by PMSF. 
The compounds are numbered sequentially :  4-((1H-benzo[d][1,2,3] triazol-1-yl)methyl)morpholine 
compound 1; 3,5,-dichloro-benzenesulfonamide   compound 2; methyl 4-aminothiophene-3-
carboxylate compound 3; 3-chlorothiophene-2-carboxylic acid , compound 4; 7-chloro-4-(piperazin-
1-yl)quinolone, compound 5; ethyl 3,5-dichloro-4-hydroxybenzoate, compound 6; 4-(piperidin-1-
ylsulfonyl)aniline, compound 7. *The TM shifts in °C are shown for each compound tested with a 
positive result for DSF, performed as described in materials and methods  at 2.5 mM final fragment 
concentration per well. Structures are drawn with ChemDraw Ultra 12.0 (CambridgeSoft). Hits from 
the primary DSF screen were re-tested twice to confirm results of the initial screen and finally 
validated for protein binding using NMR spectroscopy (as shown in Fig. 2A) (after Ciulli & Abell, 
2007; Mayer & Meyer, 1999). 
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ID Compound Structure 
IC50  
(mM) 
MIC (µg/mL) 
Growth on cholesterol 
M. bovis BCG M. tuberculosis 
2 
3,5,-dichloro-
benzenesulfonamide 
 
 
0.41 
±0.02 
<12.5 25 
8 
Benzenesulfonamide 
 
 
NI NI NI 
24 
3,5-dichlorosulfanilamide 
 
 
 
0.16±0.0
1 
25 200 
27 
3,5-dichloro-4-
hydroxybenzenesulphonic acid 
 
 
0.27 
±0.01 
>200 >200 
6 
ethyl 3,5-dichloro-4-
hydroxybenzoate 
 
 
0.52±0.0
2 
<12.5 <12.5 
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Cl Cl
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Table 2 Effects of (A)Fragment 2 and its derivatives  and  (B) fragment 6 and a derivative on HsaD enzymic activity and growth of mycobacteria 
on cholesterol as carbon source.  
NI indicates no inhibition observed at 5mM for inhibition of enzyme activity and no inhibition of growth at 200 µg/mL as described in Methods. 
IC50 values shown as average ± standard deviation (N=6). See supplementary table 1 for full list. 
 
 
  
32 
3,5-dichloro-4-hydroxybenzoic 
acid 
 
 
0.54 
±0.01 
<12.5 200 
OOH
ClCl
OH
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Table 3 Processing and refinement statistics for X-ray crystallographic structures. 
Structure HsaD - 2 HsaD - 27 HsaD - 32 
PDB Code 5JZB 5JZ9 5JZS 
Space Group I 212121 I 212121 I 212121 
 (°) 90, 90, 90 90, 90, 90 90, 90, 90 
a, b, c (Å) 82.03, 82.23, 194.25 81.73, 82.32, 193.58 81.92, 82.27, 195.13 
Processing Statistics 
Resolution Range (Å) 50.9-2.1 75.75-2.68 97.57-2.27 
Unique reflections 
a
 38,700 18,699 (2,445) 30,015 (2,024) 
Rmerge 0.134 (0.469) 0.231 (0.895) 0.109 (0.453) 
<I/σ(I)>a 8 (2.6) 4.4 (1.5) 7.7 (1.4) 
Completeness %
 a
 100 (100) 99.6 (99.0) 99.3 (57.4) 
Multiplicity
 a
 6.3 (5.3) 4.4 (4.5) 4.9 (3.1) 
Refinement Statistics 
Rwork % 23.51 24.05 23.48 
Rfree
 
%
 
 20.55 21.27 20.25 
RMS bond angle (°) 1.28 0.89 1.20 
RMS bond length (Å) 0.005 0.004 0.009 
Ramachandran Statistics
b
 
Preferred region % 97.5 98.2 98.6 
Allowed region % 2.3 1.8 1.4 
Outliers % 0.2 0 0 
a
 Numbers in parentheses are for the highest resolution shell. 
b 
Ramachandran statistics were calculated using MolProbity (Chen et al 2010).
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Figure 1. Effect of deletion of hsaD gene on M. bovis BCG.   Growth rates of ΔhsaD and 
wildtype M. bovis BCG in  MB7H9   (A)  on minimal medium containing 0.05% (v/v) 
tyloxapol, 0.05% (v/v) ethanol with no additional carbon source (B) or supplemented with , 
100 µg/mL cholesterol (C) or 100 µg/mL glycerol (D).  The symbols show  the average 
values of three independent experiments and the symbols encompass the range of values 
obtained. The intracellular survival of ΔhsaD M. bovis BCG relative to the wild-type in 
RAW264.7 cells (E) was determined as described in Methods.  The results in E are the results 
of three independent experiments in which the mean values are plotted in a staggered plot. 
All symbols represent the same sampling time points (days 0,1,2,3,4)  but are shown  as a 
cluster for clarity. 
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Figure 2A. NMR evidence of fragment binding 
 
Water-suppressed 1D 1H and STN NMR screening spectra for a representative fragment hit 
(fragment 2, at 1.2 mM) in the presence and absence of HsaD (10 uM) plus PMSF (100 uM). 
Only the fragment resonances in the aromatic region of the spectra are shown. The strong 
positive fragment signals in the presence of HsaD (purple spectrum) indicate binding, and 
this interaction is reduced by the addition of PMSF. 
 
Figure 2 B. Inhibition of HsaD by DSF hits 
Fragments identified by DSF as binding to HsaD were assayed for inhibition as described in 
materials and methods at 1 mM (hollow bars). The mean of 6 independent experiments (each 
carried out in triplicate)  ± standard deviation is shown. Fragments are numbered as shown in 
Table 1. 100% activity was defined as the rate of enzymatic HOPDA hydrolysis by 16 μg/mL 
HsaD with vehicle (no compound), which was 0.08 μmol/min/(mg protein). 
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Figure 3.  Binding of inhibitors to HsaD. (A) The active site residues of apo HsaD (Lack et 
al., 2008) are overlaid onto the active site residues of HsaD bound to fragment 27(fragment 
not shown). (B) Fragment 2, (C) Fragment 27  and  (D) Fragment 32  each bound to HsaD. In 
(A) HsaD structure with compound 2 has blue carbon atoms, apo-HsaD has gold carbon 
atoms. In (B) - (D) Green mesh is unbiased positive difference density contoured at 3σ. In (B) 
- (D) the protein is shown with blue carbon atoms, 2 is shown with grey carbon atoms, 27 
with brown carbon atoms and 32 with cyan carbon atoms. Chlorines are coloured pink and 
hydrogen bonds are black dashed lines. Interacting residues are labelled. All figures were 
generated in CCP4MG (McNicholas et al., 2011). 
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Figure 4.  Comparison of the orientation of binding of fragments to the HsaD active site. 
(A) Shows the overlaid binding orientations of compounds 27 and 32. (B) shows the overlaid 
binding orientations of compounds 2 and 27. (C) shows the electrostatic potential surface 
map of HsaD in the pocket around compound 2. (D) shows an overlay of the structure of 
HsaD bound to 2 with the structure of HsaD bound to HOPDA (PDB code 2wug) (Lack et 
al., 2010). Colour coding of carbon atoms is as per figure 3. HOPDA is shown with purple 
carbon atoms. CCP4MG was used to perform secondary structure alignments for as well as 
generating the electrostatic potential maps for (C) and (D). In frames A and B the active site 
Serine residue 114 is shown in stick format. In frames C and D the Serine residue 114 
position is indicated by an arrow. 
